Molecular Profiling for Patients with Solid Tumors: A Single- Institution Experience

e14730 Background: To assess the clinical benefit of treatment in advanced and refractory solid tumors utilizing evidence-guided molecular profiling (MP) of tumors in routine clinical practice. Methods: This retrospective observational study was conducted on patients with advanced or refractory metastatic solid tumors, whose tumor biopsy samples were referred for profiling using a multi-platform tumor profiling service (Caris Molecular Intelligence) between January 2014 and April 2017. Specific testing was performed per physician’s request and included a combination of next-generation sequencing (NGS), protein expression (IHC), gene amplification (CISH or FISH), and/or RNA fusion analysis. Results: Data of twenty five patients with solid tumors was analyzed (median age of 58 years, range 25-82 years). Patients had received a median of 2 prior lines of therapy (range 0-6). In evaluable patients, 1 (4%) patient had a complete response, 10 (46%) patients had a partial response, 5 (23%) had stable disease and 6 (27%) had progressive disease, giving a disease control rate of 73%. The majority of patients received chemotherapy (CT) alone (13; 56%). Five patients received CT combined with targeted therapy (TT), 2 received TT alone, 2 received TT combined with hormone therapy (HT), 2 have received immunotherapy and 1 received HT alone. Two patients were not evaluable for response. In responding patients, median duration of response was 7 months (3-18 months). Conclusions: The result of this study show that treatment based on Broad tumor profiling in a select group of advanced and refractory solid tumors was associated with a high disease control rate.

Download Full-text

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors

JAMA Oncology ◽

10.1001/jamaoncol.2015.5689 ◽

2016 ◽

Vol 2 (5) ◽

pp. 608 ◽

Cited By ~ 89

Author(s):

Marian H. Harris ◽

Steven G. DuBois ◽

Julia L. Glade Bender ◽

AeRang Kim ◽

Brian D. Crompton ◽

...

Keyword(s):

Solid Tumors ◽

Feasibility Study ◽

Molecular Profiling ◽

Pediatric Solid Tumors ◽

Therapeutic Decisions

Download Full-text

Metastatic solid tumors to the jaw and oral soft tissue: A retrospective clinical analysis of 44 patients from a single institution

Journal of Cranio-Maxillofacial Surgery ◽

10.1016/j.jcms.2016.05.013 ◽

2016 ◽

Vol 44 (8) ◽

pp. 1047-1053 ◽

Cited By ~ 14

Author(s):

Adepitan A. Owosho ◽

Bin Xu ◽

Arvin Kadempour ◽

SaeHee K. Yom ◽

Joseph Randazzo ◽

...

Keyword(s):

Soft Tissue ◽

Solid Tumors ◽

Clinical Analysis ◽

Single Institution ◽

Oral Soft Tissue

Download Full-text

A profile of pediatric solid tumors: A single institution experience in Kashmir

Indian Journal of Medical and Paediatric Oncology ◽

10.4103/ijmpo.ijmpo_95_16 ◽

2017 ◽

Vol 38 (4) ◽

pp. 471

Author(s):

Namita Sharma ◽

Ayesha Ahmad ◽

GullM Bhat ◽

SheikhA Aziz ◽

MohammadMaqbool Lone ◽

...

Keyword(s):

Solid Tumors ◽

Single Institution ◽

Pediatric Solid Tumors

Download Full-text

Microarray genomic expression (MAGE)-based therapy for heavily pretreated patients with metastatic solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.3064 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 3064-3064

Author(s):

Joseba Rebollo ◽

Manuel Sureda Gonzalez ◽

Francisco Jose Fernandez-Morejon ◽

Pere Bretcha ◽

Severino Rey ◽

...

Keyword(s):

Solid Tumors ◽

Biliary Tree ◽

Molecular Profiling ◽

Genomic Expression ◽

Chemotherapy Drugs ◽

Therapy Targets ◽

Potential Clinical Benefit ◽

Tumor Stages ◽

Heavily Pretreated ◽

Fresh Frozen

3064 Background: Oligonucleotide-MAGE assay to identify tumor targets and potential active drugs based on molecular profiling in chemotherapy resistant/refractory (R/R) patients with metastatic solid tumors. A potential clinical benefit has been observed by Von Hoff et al (JCO 2010;20:4877-83). Methods: Patients (pts) with R/R metastatic solid tumors were included in the study. Pathology confirmed fresh-frozen biopsies were obtained and molecular profiling oligonucleotide-MAGE (Agilent Whole Human Genome 4x44K) results, confirmed whenever possible by IHC, were used to identify potential therapy targets. Results were discussed and offered to pts and the response evaluated using RECIST criteria. OS and PFS were measured from the beginning of therapy. All pts signed informed consent. Results: From August 2010 we performed 70 procedures in 69 pts. No complications derived from the biopsy were observed. Thirty pts did not follow therapeutic recommendations and 9 pts are too early to evaluate. Thirty procedures from 29 pts are clinically evaluable. Ten pts were male and 19 female, with a median (M) age of 57 years (range 41-70). Seven pts had breast cancer, 5 NSCLC, 5 pancreas, 4 CRC, 2 ovary and one each of gastric, parotid gland, biliary tree, head and neck, esophagus and gallbladder cancers, respectively. The M previous treatments were 3 (range 1 to >6). Oligonucleotide-MAGE assay confirmed resistance in 82% of drugs previously used. A M of 3 conventional (range 0-5) and 2 experimental (range 0-4) potentially active drugs were identified. Partial response was observed in 7 (26.9%), stable disease >2 months in 12 (46.1%) and progression in 7 (26.9%) pts. Four pts were not evaluable. MPFS was 4 months (95%CI: 1.815-6.185), MOS was 6 months (95%CI: 3.4-8.6) and 1-year projected OS was 21%. Conclusions: We confirmed that it is possible to identify new potentially active drugs in heavily pretreated solid tumor pts with oligonucleotide-MAGE assay. Therapy based on these drugs showed to be active in one fourth of treated pts. These assays might be also integrated in early tumor stages to aid in the selection of chemotherapy drugs, and for this reason deserve further studies. Updated results will be presented.

Download Full-text

Routine molecular profiling of solid tumors in a community cancer center's genomic pathology laboratory.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e22088 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e22088-e22088

Author(s):

Shelly Gunn ◽

Xavier Reveles ◽

Lon S. Smith ◽

Gladys Isabel Rodriguez ◽

Amita Patnaik ◽

...

Keyword(s):

Solid Tumors ◽

New Technologies ◽

Single Gene ◽

Pancreatic Head ◽

Molecular Profiling ◽

Braf V600e ◽

Cancer Center ◽

Targeted Therapeutics ◽

Pathology Laboratory ◽

Specific Pcr

e22088 Background: Selection of targeted therapeutics for solid tumors depends upon detection of actionable genomic alterations in archival tissue. High-throughput molecular profiling at the community level would allow local pathologists to participate with oncologists in the delivery of personalized cancer medicine. Methods: Between March and December 2012, molecular profiling was performed on FFPE tumor tissue sent to Oncopath (our in-house CAP/CLIA genomic pathology laboratory) from 330 patients with diverse types of metastatic and non-resectable solid tumors. Tumor-targeted DNA was analyzed for genome-wide copy number alterations by array-based comparative hybridization (CGH), and mutation analysis (MA) using multiplex PCR with mass spectrometric genotyping (mass spec), or single gene allele-specific PCR (PCR). Results for 96 actionable genes analyzed by CGH, and MA were correlated with clinically or pre-clinically available targeted therapeutics. Actionable biomarkers for FDA approved therapies (e.g. BRAF V600E/vemurafenib) and prospective biomarkers for Phase I/II trials (e.g. CCND1 gene amplifications and CDKN2A gene deletions/CDK inhibitors) were reported for each patient. Results: Of 330 cases, 216 had at least one and as high as seven actionable biomarkers. The remaining 114 cases had either no tumor specific changes (n=17) or non-actionable oncogenic changes (n=97). The most commonly analyzed tumors were breast, brain, lung, colorectal, pancreatic, head & neck, and ovarian. Rare tumor types with positive biomarkers included an HRAS Q61R positive adenoid cystic carcinoma and a BRAF V600E positive pleomorphic xanthroastrocyoma. Tumor DNA was stored for 100% of patients and all cases were reported synoptically listing actionable biomarkers with therapeutic recommendations. Conclusions: Molecular profiling in a community cancer center facilitates biomarker detection for rational direction of patients to targeted therapeutics. New technologies for detection of actionable biomarkers will continue to be implemented in our center to improve the likelihood of effective treatment for each individual patient’s tumor.

Download Full-text